Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
02
08
2022
pubmed:
27
8
2022
medline:
27
10
2022
entrez:
26
8
2022
Statut:
ppublish
Résumé
The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6-11 years with moderate-to-severe AD not adequately controlled with topical therapies or when those therapies are not advisable. The aim of this study was to evaluate in real life the effectiveness and safety of dupilumab in the treatment of children aged from 6 to 11 years. Demographic and clinical data of children aged 6-11 years, affected by moderate-to-severe AD and treated with dupilumab, were retrospectively collected from 24 dermatological and paediatric referral centres. Dupilumab was administered subcutaneously at an induction dose of 300 mg on day (D) 1, followed by 300 mg on D15 and 300 mg every 4 weeks. Disease severity was assessed at baseline and after week 2 (W2), W4 and W16 of dupilumab therapy using Eczema Area Severity Index (EASI), Pruritus Numerical Rating Scale (P-NRS) and Sleep NRS (S-NRS) and Children's Dermatology Life Quality Index (c-DLQI) score. A total of 55 AD children (24 males [43.64%], 31 females [56.36%]; mean age 9.35 ± 1.75 years) were included. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to W16 of treatment with dupilumab. In particular, at W16 the proportion of patients achieving EASI75 was 74.54%. Moreover, at the same timepoint a significant mean percentage reduction for P-NRS, S-NRS and c-DLQI was also observed (68.39%, 70.22% and 79.03%, respectively). Our real-life data seem to confirm the effectiveness of dupilumab in paediatric patients on all disease aspects, including extent and severity of signs, intensity of symptoms, sleep and QoL, with a good safety profile.
Sections du résumé
BACKGROUND
BACKGROUND
The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6-11 years with moderate-to-severe AD not adequately controlled with topical therapies or when those therapies are not advisable.
OBJECTIVES
OBJECTIVE
The aim of this study was to evaluate in real life the effectiveness and safety of dupilumab in the treatment of children aged from 6 to 11 years.
METHODS
METHODS
Demographic and clinical data of children aged 6-11 years, affected by moderate-to-severe AD and treated with dupilumab, were retrospectively collected from 24 dermatological and paediatric referral centres. Dupilumab was administered subcutaneously at an induction dose of 300 mg on day (D) 1, followed by 300 mg on D15 and 300 mg every 4 weeks. Disease severity was assessed at baseline and after week 2 (W2), W4 and W16 of dupilumab therapy using Eczema Area Severity Index (EASI), Pruritus Numerical Rating Scale (P-NRS) and Sleep NRS (S-NRS) and Children's Dermatology Life Quality Index (c-DLQI) score.
RESULTS
RESULTS
A total of 55 AD children (24 males [43.64%], 31 females [56.36%]; mean age 9.35 ± 1.75 years) were included. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to W16 of treatment with dupilumab. In particular, at W16 the proportion of patients achieving EASI75 was 74.54%. Moreover, at the same timepoint a significant mean percentage reduction for P-NRS, S-NRS and c-DLQI was also observed (68.39%, 70.22% and 79.03%, respectively).
CONCLUSIONS
CONCLUSIONS
Our real-life data seem to confirm the effectiveness of dupilumab in paediatric patients on all disease aspects, including extent and severity of signs, intensity of symptoms, sleep and QoL, with a good safety profile.
Identifiants
pubmed: 36028611
doi: 10.1007/s40272-022-00531-0
pii: 10.1007/s40272-022-00531-0
pmc: PMC9417930
doi:
Substances chimiques
dupilumab
420K487FSG
Emollients
0
Antibodies, Monoclonal
0
Adrenal Cortex Hormones
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
671-678Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70:836–45.
doi: 10.1111/all.12619
Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population. A cross sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126:417–28.
doi: 10.1016/j.anai.2020.12.020
Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019;6(12):133.
pmcid: 6955769
Axon E, Chalmers JR, Santer M, et al. Safety of topical corticosteroids in atopic eczema: an umbrella review. BMJ Open. 2021;11(7): e046476.
doi: 10.1136/bmjopen-2020-046476
Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.
doi: 10.1016/j.jaad.2014.03.023
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:850–78.
doi: 10.1111/jdv.14888
Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: international Eczema council consensus statement. Br J Dermatol. 2018;178:768–75.
doi: 10.1111/bjd.15928
Lebwohl M, Alexis AF, Beck LA, et al. Systemic therapies for moderate-to-severe atopic dermatitis: expert perspectives in practice. J Drugs Dermatol. 2019;18:122–9.
pubmed: 30794360
Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol. 2013;132:774-774.e6.
doi: 10.1016/j.jaci.2013.03.016
Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol. 2017;76:281–5.
doi: 10.1016/j.jaad.2016.09.021
Regeneron pharmaceuticals. DUPIXENTVR prescribing information. Tarrytown, NY; 2018 October. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–93.
doi: 10.1016/j.jaad.2020.06.054
https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s042lbl.pdf
Brunner PM, He H, Pavel AB, et al. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. J Am Acad Dermatol. 2019;81(2):510–9.
doi: 10.1016/j.jaad.2019.04.036
Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is T
doi: 10.1016/j.jaci.2016.07.013
Igelman S, Kurta AO, Sheikh U, et al. Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review. J Am Acad Dermatol. 2020;82(2):407–11.
doi: 10.1016/j.jaad.2019.10.010
Lasek A, Bellon N, Mallet S, et al. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6–11 years): data from a French multicenter retrospective cohort in daily practice. J Eur Acad Dermatol Venereol. 2022. https://doi.org/10.1111/jdv.18450 .
doi: 10.1111/jdv.18450
pubmed: 35854650
pmcid: 9349726
Stingeni L, Hansel K, Antonelli E, Bello GD, Patruno C, Napolitano M, Fabbrocini G, Grieco T, Pellacani G, Fargnoli MC, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther. 2021;34(5): e15035.
doi: 10.1111/dth.15035
Hansel K, Patruno C, Antonelli E, Dal Bello G, Napolitano M, Fabbrocini G, Grieco T, Pellacani G, Fargnoli MC, Esposito M, et al. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. Clin Exp Dermatol. 2021. https://doi.org/10.1111/ced.14862 .
doi: 10.1111/ced.14862
pubmed: 34309892
pmcid: 8444687
Patruno C, Fabbrocini G, Longo G, et al. Dupilumab for Atopic Dermatitis of the Elderly (DADE) Study Group. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581–6.
doi: 10.1007/s40257-021-00597-5
Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958–64. https://doi.org/10.1111/jdv.17094 .
doi: 10.1111/jdv.17094
pubmed: 33332697
Napolitano M, Ferrillo M, Patruno C, Scalvenzi M, D’Andrea M, Fabbrocini G. Efficacy and safety of dupilumab in clinical practice: one year of experience on 165 adult patients from a tertiary referral centre. Dermatol Ther (Heidelb). 2021;11(2):355–61. https://doi.org/10.1007/s13555-021-00505-z .
doi: 10.1007/s13555-021-00505-z
pubmed: 33712985
pmcid: 8018995
Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):161.
doi: 10.2340/00015555-3511
Cook F, Conway LJ, Giallo R, Gartland D, Sciberras E, Brown S. Infant sleep and child mental health: a longitudinal investigation. Arch Dis Child. 2020;105(7):655–60.
doi: 10.1136/archdischild-2019-318014
Huhdanpää H, Morales-Muñoz I, Aronen ET, Pölkki P, Saarenpää-Heikkilä O, Paunio T, et al. Sleep difficulties in infancy are associated with symptoms of inattention and hyperactivity at the age of 5 years: a longitudinal study. J Dev Behav Pediatr JDBP. 2019;40(6):432–40.
doi: 10.1097/DBP.0000000000000684
Nguyen CM, Koo J, Cordoro KM. Psychodermatologic effects of atopic dermatitis and acne: a review on self-esteem and identity. Pediatr Dermatol. 2016;33:129–35.
doi: 10.1111/pde.12802
Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. Children (Basel). 2021;8(11):1057.
pubmed: 34828770
pmcid: 8619705
Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–70.
doi: 10.1111/bjd.19460
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase III trial. Lancet. 2017;389:2287–303.
doi: 10.1016/S0140-6736(17)31191-1
de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178:1083–101.
doi: 10.1111/bjd.16156
Colonna C, Zussino M, Monzani NA, Ponziani A, Cavalli R. Treatment of children from 6 to 11 years old affected by moderate-severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy. J Eur Acad Dermatol Venereol. 2022;2:2.